ArticleScience translational medicine2021
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Establishing a Clinically Relevant Radiation Therapy Method for Preclinical Medulloblastoma Research.Advances in radiation oncology · 2026Article
- Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus.British journal of cancer · 2026Article
- Paediatric therapeutic development workshop on medulloblastoma.British journal of cancer · 2026Review
- Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors.Science advances · 2026Article
- Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines.Discover oncology · 2026Article
- Article
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.Scientific reports · 2025Article
- Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target.Cancer cell · 2025Article
- Antitumor Activity of Radiation Therapy Combined with Checkpoint Kinase Inhibition in SHH/International journal of molecular sciences · 2025Article
- Article
- CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549.Molecular & cellular oncology · 2025Article
- Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.Current oncology (Toronto, Ont.) · 2024Article
- The pivotal role of irradiation-induced apoptosis in the pathogenesis and therapy of medulloblastoma.Cancer reports (Hoboken, N.J.) · 2024Review
- Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.Cancer research communications · 2023Article
- YB1 modulates the DNA damage response in medulloblastoma.Scientific reports · 2023Article
- Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo.Molecular cancer therapeutics · 2023Article
- Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors.Frontiers in oncology · 2023Article
- Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma.Molecular cancer therapeutics · 2022Article
- The SKP2-p27 axis defines susceptibility to cell death upon CHK1 inhibition.Molecular oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 4 countries.
Raelene EndersbyBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia. raelene.endersby@telethonkids.org.au nick.gottardo@health.wa.edu.au.ORCID 0000-0003-3554-2769
Jacqueline WhitehouseBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Allison PribnowDivision of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
Mani KuchibhotlaBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0002-6348-4087
Hilary HiiBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0002-8431-5725
Brooke CarlineBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0002-8061-4170
Suresh GandeBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Jennifer StripayDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.ORCID 0000-0002-0039-8675
Mathew AncliffeBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Meegan HowlettBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0003-4332-6572
Tobias SchoepBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Courtney GeorgeBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Clara AndradasBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Patrick DyerBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Marjolein SchluckBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0002-7939-2072
Brett PattersonBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.
Silvia K Tacheva-GigorovaTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Matthew N CooperBiometrics, Telethon Kids Institute, University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0003-1139-3682
Giles RobinsonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.ORCID 0000-0001-7441-9486
Clinton StewartDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.ORCID 0000-0002-1546-9720
Stefan M PfisterHopp Children's Cancer Center (KiTZ) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
Marcel KoolHopp Children's Cancer Center (KiTZ) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
Till MildeHopp Children's Cancer Center (KiTZ) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.ORCID 0000-0002-7267-1052
Amar GajjarDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.ORCID 0000-0001-5019-0699
Terrance JohnsBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia.ORCID 0000-0002-8874-4543
Robert J Wechsler-ReyaTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-7463-8352
Martine F RousselDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.ORCID 0000-0002-1740-8139
Nicholas G GottardoBrain Tumour Research Program, Telethon Kids Institute, Nedlands, WA 6009, Australia. raelene.endersby@telethonkids.org.au nick.gottardo@health.wa.edu.au.ORCID 0000-0002-1082-6776
The Kids Research Institute Australia · AUSt. Jude Children's Research Hospital · USHeidelberg University · DEDiscovery Institute · USPalo Alto University · USRadboud University Nijmegen · NL
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MThe DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MMouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4MNCI NIH HHS P01 CA096832NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA159859
Abstract
Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely,
Indexed as
Cerebellar NeoplasmsMedulloblastomaAnimalsCell CycleCell Cycle CheckpointsCell Line, TumorDNAHumansMiceProtein Kinase InhibitorsDNAProtein Kinase Inhibitors
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.